Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old

EyeGene

Status and phase: Enrolling; Phase 3; Phase 2

Conditions: Meningococcal Infections

Treatments: Biological: Menveo; Biological: EG-MCV4

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT07204457

EG-MCV4-P3

Details and patient eligibility

About

Phase 2/3 study to evaluate immunogenicity and safety in healthy adult participants following a single dose administration of Meningococcal (groups A, C, W-135, and Y) conjugate vaccine

Enrollment: 1,123 estimated patients

Sex: All

Ages: 19 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy males and females aged 19 to 55 years.
• Individuals who have been fully informed about the clinical trial, understand the details, and voluntarily agree to participate by providing written informed consent.
• Individuals who are available for all scheduled visits, including phone calls and in-person appointments, for the duration of the study.

Exclusion criteria

• History of prior disease caused by N. meningitidis.
• Contact with a person infected with N. meningitidis within 60 days of screening.
• Prior receipt of a meningococcal vaccine or a vaccine containing a meningococcal antigen.
• History of or planned vaccination with any other vaccine within 4 weeks before or after administration of the investigational product.
• History of fever (≥ 38°C) within 3 days of screening, or a history of a significant acute infectious disease within 7 days of screening, or a chronic infectious disease within 4 weeks of screening.
• History of Hepatitis B or C at the time of screening.
• Presence of any significant acute, chronic, or progressive disease that, in the opinion of the investigator, could interfere with the conduct or completion of the study.
• History of malignancy or high-risk malignant disease within 5 years before the investigational product administration.
• History of epilepsy, progressive neurological disease, or Guillain-Barré Syndrome.
• History of anaphylaxis.
• History of systemic urticaria within 5 years of the investigational product administration.
• Hypersensitivity to the active substance, diphtheria toxoid (CRM197), or any other excipient, or a history of a life-threatening reaction to a vaccine containing similar components.
• Hypersensitivity to the investigational vaccine, any of its components, or latex.
• History of any therapy that could affect the immune system within 6 months of screening.
• History of immunodeficiency disease, or a family history of such a disease.
• Receipt of any parenteral immunoglobulin preparation, blood product, or plasma derivatives within 90 days of screening, or planned administration during the study period.
• History of platelet-related or hemorrhagic disorders or a history of excessive bleeding or bruising after intramuscular injection or venipuncture.
• Current treatment with anticoagulants or new antiplatelet agents.
• History of organ or bone marrow transplantation.
• Suspected history of drug or alcohol abuse within 1 year before the investigational product administration.
• Individuals unwilling to use a medically acceptable method of contraception for the duration of the clinical trial.
• Pregnant or lactating women.
• Receipt or planned receipt/application of another investigational drug or medical device within 6 months prior to study participation.
• Presence of a significant abnormality on a screening test, or any other reason that, in the opinion of the investigator, makes the individual unsuitable for the study.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

1,123 participants in 3 patient groups

EG-MCV4 (Test group 1)

Experimental group

Description:

Healthy adults received 0.5 mL single intramuscular dose on Day 0.

Treatment:

Biological: EG-MCV4

EG-MCV4 (Test group 2)

Experimental group

Description:

Healthy adults received 0.25 mL single intramuscular dose on Day 0.

Treatment:

Biological: EG-MCV4

Menveo

Active Comparator group

Description:

Healthy adults received 0.5 mL single intramuscular dose on Day 0.

Treatment:

Biological: Menveo